Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. - Wikidata - wikimedia - TriplyDB

Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer.

Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer.

http://www.wikidata.org/entity/Q43683844

about

The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.The effects of medications on circulating levels of cardiac natriuretic peptides Dexrazoxane does not protect against doxorubicin-induced damage in young rats Diagnostic Strategies for Early Recognition of Cancer Therapeutics-Related Cardiac Dysfunction.Assessment of cardiotoxicity with cardiac biomarkers in cancer patients.Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity.Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity.Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity Natriuretic peptide testing in primary care patients.The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature.New and emerging biomarkers of heart failure.Late effects of childhood leukemia therapy.Cardiotoxicity of childhood cancer treatment: update and current knowledge on long-term follow-up.Using cardiac biomarkers and treating cardiotoxicity in cancer.Educational paper: decreasing the burden of cardiovascular disease in childhood cancer survivors: an update for the pediatrician.The potential and limitations of plasma BNP measurement in the diagnosis, prognosis, and management of children with heart failure due to congenital cardiac disease: an update.BNP in children with congenital cardiac disease: is there now sufficient evidence for its routine use?Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker?The Role of Biomarkers in Detection of Cardio-toxicity.Alternative Biomarkers for Combined Biology.Biomarkers for monitoring chemotherapy-induced cardiotoxicity.Cardio-oncology: the Nuclear Option.Can we find a good biochemical marker of early cardiotoxicity in children treated with haematopoietic stem cell transplantation?Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats.Plasma natriuretic peptides levels and echocardiographic findings in late subclinical anthracycline toxicity.Cardiac response to doxorubicin and dexrazoxane in intact and ovariectomized young female rats at rest and after swim training.Cardiac complications of chemotherapy: role of biomarkers.The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy.

P2860

Q26743433-7F7CC325-EC64-4C28-96A1-B39CB29796F7 Q27027354-D5C9F880-801D-44B7-80D2-CD1C9D519EAD Q28212913-A9C3ACC2-680B-4899-8F14-E620DE2D8A4A Q28572861-F91C3612-8E86-40DE-99BA-14914712F781 Q33565936-E3F34CE3-04ED-4C91-9193-6A7EA9F5C610 Q33896047-C243497F-69A6-4236-8E35-E8875BE59129 Q35797623-92391741-5800-4EE7-ADB9-05C0DE00DF1B Q36150546-03EA4418-C479-436B-A436-441523E11308 Q36825438-9C5A385F-5DEE-40F3-A2A3-5E67F59FB148 Q37230118-A9481270-AFC0-4953-AD18-96D8C52665F1 Q37291305-C53E19A0-5308-4128-A478-8F87CE055EA4 Q37292501-2BB817D7-E7DC-4C09-9149-1B8B78D74C75 Q37514230-E4B1A626-749D-4DF4-9F9F-493527EDB65F Q37892981-12380C1A-66B1-4642-B57C-9FD12F2D77CC Q38021523-C920927E-241D-46ED-9F07-9EB122A55597 Q38069202-B987DB4D-68BA-478D-BA12-597E648C90AC Q38077713-6A34C9AA-7042-458E-AC79-7007AE57CE03 Q38182858-DE642FB5-DE3E-4E71-8231-11C09D076F66 Q38324210-EE86A1AE-D01F-46A3-900B-D5303534726B Q38727423-5E69AC36-3E1A-41CF-8A9B-7278D8082CF0 Q38728535-2EEEC28E-515D-41DA-919D-02169788A535 Q38747992-8BFB6817-937A-4A0F-BDC4-BF0F0295D16B Q39053477-B36AED0E-4E23-42A0-8151-14D940A0C8B1 Q39185620-8DE8C5F6-AE08-4A32-A1DB-705029AC6E1C Q41030597-AF39FD81-09C7-4D9C-8159-C0991D617E61 Q43151456-AD3569E4-498A-44E3-AE2D-56A9FA18CCE1 Q48809762-9C29196E-9BAC-4A77-8C6A-9E63983E9865 Q51350978-32394ACD-EF28-4329-BF96-749C6C51EE77 Q51739297-F6E1FE3E-0697-4745-91C3-C74D9C3A16B2 Q52982588-9FB21E4D-C08E-4B6B-931D-BDE5E472230F

P2860

Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer.

http://www.wikidata.org/entity/Q43683844

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Plasma levels of natriuretic p ...... ction in children with cancer.

@en

Plasma levels of natriuretic p ...... ction in children with cancer.

@nl

type

label

Plasma levels of natriuretic p ...... ction in children with cancer.

@en

Plasma levels of natriuretic p ...... ction in children with cancer.

@nl

prefLabel

Plasma levels of natriuretic p ...... ction in children with cancer.

@en

Plasma levels of natriuretic p ...... ction in children with cancer.

@nl

P1433

Q43683844-B4E862DD-536A-4BE4-8940-3037F76B8D33

P1476

Q43683844-336329C4-DFB0-4B3E-AAFB-A901F7CCCAA1

P2093

Q43683844-44F6C001-E4C6-46F6-BAE7-75B4598C898C

Q43683844-572E2ACB-C2F2-4DC6-8868-8DDE315AC918

Q43683844-65822BB8-73E6-4118-AC82-CE9085E0F12C

Q43683844-73F1CD8E-7345-4A71-9723-DDCD64376CD4

Q43683844-9250A89D-418A-4016-9639-5D8AFD7E8870

Q43683844-9A2610A9-C371-4983-9A41-ECB7B26375ED

P2860

Q43683844-01720F6E-81CD-4546-90B6-AA39648F2683

Q43683844-141139E5-FF80-41BF-B5A5-881301585271

Q43683844-160FBEE7-BBAE-4981-BFBB-0363F07ADE87

Q43683844-32FDCD7D-70B9-433B-B48E-DB2B8B7D4723

Q43683844-3C713899-D1CA-4F42-8FB3-F15DDFEEB501

Q43683844-5170538F-9E14-4996-99B5-5280C357A177

Q43683844-555359A3-8F15-4B84-A526-C353892A9DA3

Q43683844-5A8DD7CE-FA67-4552-8C91-53A4A53DE554

Q43683844-68E09BEF-7E3A-4E07-82E9-760B7E088296

Q43683844-8501F060-CED6-499D-9B2B-DAF31A8BD32A

P304

Q43683844-F99C2EA2-8BC9-45E2-86F7-F97F5E237308

P31

Q43683844-1EB5A1DA-CF85-41C7-98DB-64F88A183C73

P356

Q43683844-B4175725-65C3-4397-96AE-7BF696C49DBF

P433

Q43683844-849AD860-6A3D-4284-A8A2-6E670C57E1AC

P478

Q43683844-1964DD4C-AD3F-4FB6-A1B0-F65B770FE03E

P577

Q43683844-E7DF1306-43DF-45BA-B865-30FC40F06000

P698

Q43683844-F5B2C32B-E489-46F6-9442-55C075CAA33D

P356

P1433

Pediatric Blood & Cancer

P1476

Plasma levels of natriuretic p ...... ction in children with cancer.

@en

P2093

Hayakawa H

http://www.w3.org/2001/XMLSchema#string

Hirayama M

http://www.w3.org/2001/XMLSchema#string

Hori H

http://www.w3.org/2001/XMLSchema#string

Ito M

http://www.w3.org/2001/XMLSchema#string

Komada Y

http://www.w3.org/2001/XMLSchema#string

Sakurai M

http://www.w3.org/2001/XMLSchema#string

P2860

Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood

Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients.

Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods

Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide.

Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology.

Assessment of diastolic function of the heart: background and current applications of Doppler echocardiography. Part II. Clinical studies.

Review of tests for monitoring doxorubicin-induced cardiomyopathy.

Cardiac toxicity 4 to 20 years after completing anthracycline therapy.

Alterations in left ventricular diastolic function with doxorubicin therapy.

P304

4-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MPO.1155

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P577

2001-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11466716

http://www.w3.org/2001/XMLSchema#string